BioLineRx and Hemispherian Report Encouraging GLIX1 Combination Results in Ovarian Cancer Models
Key Points
- GLIX1 enhanced the activity of three PARP inhibitors in laboratory studies of HR-proficient ovarian cancer cells.
- In a mouse model using patient-derived ovarian tumor tissue, low-dose GLIX1 plus olaparib significantly slowed tumor growth compared with a vehicle control.
- The combination showed greater antitumor activity than either drug alone at higher doses, with tumor growth inhibition comparable to cisplatin in that model.
- BioLineRx plans to add an ovarian cancer arm during the expansion phase of its ongoing GLIX1 clinical trial.
- These are preclinical findings—not evidence of safety or effectiveness in ovarian cancer patients.
BioLineRx (NASDAQ: BLRX) and Hemispherian presented findings at ESMO 2026 suggesting that GLIX1 could help extend the activity of PARP inhibitors to ovarian cancers that have shown limited sensitivity to these drugs.
The research focused on HR-proficient tumors, which retain a DNA-repair capability that can limit PARP inhibitor activity. The companies are investigating whether GLIX1 can make those cancer cells more vulnerable to treatment.
Laboratory Studies Show Combination Activity Across Three Drugs
Researchers combined GLIX1 with olaparib, veliparib and niraparib across several HR-proficient ovarian cancer cell lines.
All three combinations showed reproducible synergy, meaning their combined effects exceeded what the analysis would predict from the drugs acting independently. Reported ZIP synergy scores ranged from 10.9 to 43.2.
GLIX1 activates the TET2 pathway and is designed to increase DNA damage in tumor cells. The proposed combination aims to overwhelm those cells’ ability to repair the damage.
Low-Dose Combination Slows Tumor Growth in Mouse Study
In a 28-day study using a patient-derived ovarian cancer model, low-dose GLIX1 plus olaparib significantly inhibited tumor growth compared with the vehicle control.
The combination also showed greater activity than higher-dose GLIX1 or olaparib alone, and tumor growth inhibition comparable to cisplatin.
Those findings support further testing, but they do not establish that the combination matches chemotherapy in patients or that lower doses would be safer in humans.
Ovarian Cancer Expansion Is Planned for Ongoing Trial
GLIX1 is already being evaluated in a Phase 1/2a glioblastoma trial, where BioLineRx says three dose-level patient cohorts have been enrolled.
The company plans to include an ovarian cancer arm during the trial’s expansion phase. The announcement does not provide a start date or report clinical results for the ovarian cancer combination.
Investor Takeaway: Potential Beyond Glioblastoma, With Human Evidence Still Needed
For BLRX investors, the results support exploring GLIX1 in another cancer setting and alongside an established drug class.
The key next step is determining whether the preclinical activity translates into tolerable dosing and meaningful benefits in patients. The findings do not yet establish that GLIX1 overcomes PARP inhibitor resistance in humans.
